Saturday, April 15, 2017

Lupin Limited - Avoid

I was attracted last year by impressive product range and fundamentals. Alas i bought around 1625 and exited around 1540 after holding for few months !

Company Background :-
Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas.

The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil. It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health.

The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.

For more info about company -

Stock Performance :
Not going anywhere - gets support around INR 1400 and struggling to get past 1600

Future Outlook :
Pharma industry is under cloun many blue chips are languishing and for the next year or 18 Months we do not expect any spectacular movement